Background: Acute kidney injury (AKI) commonly occurs in patients with sepsis. Acetaminophen (APAP) has been shown to inhibit lipid peroxidation and, thus, may be renal protective in patients with sepsis. Objective: The objective of this study was to determine the effect of APAP on AKI in patients with sepsis. Methods: This was a retrospective cohort study conducted at 2 affiliated academic medical centers in the United States. Adult patients who were admitted to the intensive care unit with a diagnosis of severe sepsis were included. Patients were categorized based on whether APAP was received within the first 7 days of hospitalization (APAP or no APAP groups). The primary outcome measure was occurrence or increase in AKI stage from admission. Multivariate logistic regression analyses were used to adjust for potential confounders. Results: There were 238 patients who were included in the study cohort. Of these, 122 received APAP and 116 did not receive APAP. AKI or exacerbation occurred in 16.4% (n = 20) of patients in the APAP group and 19.8% (n = 23) of patients in the no APAP group (P = 0.505). After adjusting for the most important confounders, there was no significant association between APAP use and AKI (odds ratio = 1.2; 95% CI = 0.6-2.4; P = 0.639). Conclusion: APAP use in critically ill patients with sepsis may not reduce the occurrence or exacerbation of AKI.
Introduction
Sepsis is common in patients admitted to the intensive care unit (ICU), occurring in close to 40% of patients. 1 In sepsis, hemolysis results in the production of cell-free hemoglobin, reactive oxygen species, lipid peroxidation, and finally cellular injury. 2, 3 This contributes to organ dysfunction, including acute kidney injury (AKI). AKI may occur in more than 20% of patients with sepsis. 4 In animal models, acetaminophen (APAP) has been shown to ameliorate this process by inhibiting lipid peroxidation and, thus, may be renal protective. 5 In 1 small trial (n = 40) in patients with sepsis, APAP use was associated with significantly lower concentrations of F 2 -isoprostanes, which is a marker of lipid peroxidation. 3 Patients who received APAP also had lower serum creatinine values after the first 2 days of the study. The results suggest that APAP use soon after ICU admission in patients with sepsis may reduce oxidative injury and prevent renal dysfunction if detectable plasma cell-free hemoglobin levels are present. However, the study did not utilize official definitions to characterize AKI.
Studies have also evaluated the effect of APAP on other outcomes such as mortality in patients with sepsis, with conflicting results. 6, 7 However, neither of these investigations evaluated the effect of APAP on the incidence of AKI. Thus, there is little evidence regarding the potential renal protective effects of APAP using validated criteria for diagnosing AKI. Given this gap in the literature, studies are needed to determine the effect of APAP on the prevention AKI by measuring laboratory and other parameters that closely reflect clinical practice.
The primary objective of this study was to evaluate the effect of APAP for the prevention and amelioration of AKI as defined by expert panel guidelines in patients with sepsis. We hypothesized that APAP use in these patients would be associated with decreased AKI. The secondary outcomes were to evaluate the effect of APAP on hospital length of stay and in-hospital mortality in patients with sepsis. 
Methods

Study Design and Setting
This was a retrospective cohort study conducted at 2 affiliated academic institutions in the United States. Both institutions used the same electronic medical record and had the same protocol in place for the management of patients with sepsis. The protocol was constructed within the electronic medical record and was based on the surviving sepsis campaign guidelines for the management of sepsis. 8 The order set within the electronic medical record did allow selection of therapies based on provider preference. Also, the selection of APAP was based on provider discretion. The University's Institutional Review Board approved the study prior to data collection. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) criteria were followed for all aspects of the study. 9 
Patient Selection
Adult patients (18 years or older) who were admitted to the ICU were included consecutively between November 1, 2013, and September 1, 2014. The medical record was queried using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code for severe sepsis (995.92). This was verified based on guideline definitions during a manual screening process. Patients were excluded if they had stage 3 AKI on admission ( 
Data Collection
The data collected from electronic medical records included age, sex, race, weight, laboratory and clinical data needed to calculate the SOFA (Sequential Organ Failure Assessment) score, urine output, serum creatinine, blood glucose, lactate, white blood cell count, temperature, surgical procedures, service type (surgical or medical), source of infection, organism isolated, APAP data, and information pertaining to other potentially nephrotoxic medications (nonsteroidal anti-inflammatory agents, angiotensin-converting enzyme inhibitors, vancomycin, β-lactam antibiotics, aminoglycosides, and contrast media). Data were also obtained pertaining to the use of hydrocortisone, albumin, vasopressors, and inotropes for the management of septic shock. All ICD-9-CM diagnoses codes were obtained to calculate the Charlson Comorbidity Index (CCI). 10 Data on length of ICU stay, length of hospital stay, duration of mechanical ventilation, and in-hospital mortality were also collected.
Outcome Measures
The primary outcome measure was the development of AKI (stage 1 or higher) or an increase of AKI stage (for patients with stage 1 or 2 AKI) during the first week of hospitalization. The stage of AKI was based on the Kidney Disease Improving Global Outcomes guidelines (Table 1) . 11 During the data collection process, we found that urine output measures were missing or inaccurate in the medical record to use this variable in staging. Thus, we primarily relied on serum creatinine values. To minimize errors in staging and investigator bias, an automated algorithm was used to stage patients based on baseline and daily serum creatinine values. Two investigators independently and manually verified this staging. The stage was assessed on admission (initial stage) and then evaluated for an increase (final stage). Thus, we were interested in evaluating if APAP use prevented the development of AKI or exacerbation of the stage of AKI. The primary outcome is a dichotomous variable indicating AKI/exacerbation versus no AKI/exacerbation. The secondary outcomes were length of hospital stay (days) and in-hospital mortality.
Statistical Analyses
The cohort was categorized as APAP versus no APAP within the first 7 days of hospitalization. Categorical variables were compared using the Fisher's exact test. Continuous variables were analyzed using either a Student t-test for normally distributed data or Wilcoxon rank-sum test for nonnormally distributed data. A multivariate logistic regression analysis was conducted for the primary outcome. The primary predictor of interest was the administration of APAP. In addition, we considered age, CCI, and SOFA score to be the most important independent variables to be added to the model. The model was checked for interactions. We had to limit the number of covariates to avoid overfitting the model. To overcome this problem, we also conducted a propensity score analysis. Propensity scores were calculated for each participant using all covariates, including any that were imbalanced between groups. The effect of APAP was then adjusted for this propensity score. We assumed the proportions of AKI in the control and APAP groups to be 25% and 10%, respectively (absolute difference of 15%). 4 Using a 2-sided α of 0.05 and power of 80%, we estimated that 100 patients would be needed in each group. All statistical evaluations were performed using STATA 13 (College Station, TX). An a priori α of 0.05 was used for all analyses.
Results
Overall Cohort
A total of 430 patients were screened for inclusion. Of these, 109 had stage 3 AKI on admission, 43 did not have sepsis present on admission, 31 did not have sepsis based on manual screening, and 9 died within 24 hours of admission. Thus, 238 patients were included in the final cohort. Of these, 122 received APAP and 116 did not receive APAP. In the overall cohort, the mean age was 58 ± 18 years, 54.2% (n = 129) were male, and the majority was Caucasian (53.8%, n = 128) or Hispanic (33.2%, n = 79). On admission, 58.8% (n = 140) had no AKI, 21.9% (n = 52) had stage 1 AKI, and 19.3% (n = 46) had stage 2 AKI. In patients who received any APAP, the median cumulative dose in the first 3 days was 1225 mg (interquartile range [IQR] = 650-1950 mg). Baseline comparisons between groups are reported in Table 2 . There were some imbalances between groups with regard to age, comorbidities, SOFA score, sources of infection, and medications used.
Main Results
AKI or exacerbation occurred in 16.4% (n = 20) of patients in the APAP group and 19.8% (n = 23) of patients in the no APAP group (P = 0.505). The initial and final AKI stage for each group is given in Table 3 . After adjusting for the most important confounders (age, CCI, and SOFA score), there was no significant association between APAP use and AKI (odds ratio [OR] = 1.2; 95% CI = 0.6-2.4; P = 0.639). The full model is reported in Table 4 . No interactions were identified in the model. In the propensity score analysis, the use of APAP was still not significantly associated with AKI (OR = 1.64; 95% CI = 0.62-4.32; P = 0.315).
The median duration of mechanical ventilation was 2 days (IQR = 0-5 days) in the APAP group and 2 days (IQR = 0-7 days) in the no APAP group (P = 0.335). ICU length of stay was also similar between the APAP (3 days, IQR = 2-10 days) and no APAP groups (5 days, IQR = 2-10 days; P = 0.507). Hospital length of stay was 10 days (IQR = 5-16 days) in the APAP group and 8 days (IQR = 5-16 days) in the no APAP group (P = 0.349). In-hospital death occurred in 18.0% (n = 22) of patients in the APAP group and 36.2% (n = 42) of patients in the no APAP group (P = 0.002). After adjusting for propensity score, there was no significant association between APAP use and in-hospital mortality (OR = 0.58; 95% CI = 0.24-1.41; P = 0.229).
Discussion
The key finding in this study is that the use of APAP was not associated with a reduction of AKI or length of stay in patients with sepsis. The large reduction in in-hospital mortality in patients who received APAP on bivariate analysis was somewhat unexpected. However, we adjusted for potential confounders and also performed a propensity analysis. The difference in in-hospital mortality did not hold true in the propensity analysis, which indicates that there was some selection bias present. For instance, APAP use in this study was likely related to temperature control or analgesia rather than to prevent organ failure from elevated cell-free hemoglobin. This is highlighted by the fact that patients who received APAP also had a higher temperature. We anticipated this phenomenon and wanted to evaluate if the use of APAP also improved outcomes and reduced AKI as has been suggested in previous preliminary investigations. Our results build on previous studies because we used official definitions to characterize AKI that can be more directly applied to clinical practice.
A previous retrospective study (n = 391) evaluated the impact of cell-free hemoglobin on mortality rates and the potential protective effects of APAP in patients with sepsis. 6 The study found that mortality was less in patients with undetectable versus detectable cell-free hemoglobin concentrations (8.1% vs 24.9%, respectively; P ≤ 0.001). Furthermore, compared with survivors, nonsurvivors had higher cell-free hemoglobin concentrations (median = 10 vs 20 mg/dL, respectively; P = 0.002). Also, APAP use reduced mortality in those with elevated cell-free hemoglobin levels (OR = 0.48; 95% CI = 0.25-0.91; P = 0.026). No data were provided on the relationship between APAP and other variables such as serum creatinine, urine output, and length of stay. The study suggested that in patients with elevated cell-free hemoglobin levels, APAP use could have a beneficial effect on patient outcomes. Subsequent to this investigation, the same authors conducted a small (n = 40) randomized, double-blind, placebo-controlled trial evaluating the effects of APAP (1 g orally every 6 hours for 3 days) in patients with severe sepsis and detectable concentrations of cell-free hemoglobin. 3 There was no significant difference between the APAP and placebo groups for the primary study end point of F 2 -isoprostanes (an indicator of lipid peroxidation) on day 3 (30 pg/mL, IQR = 24-41, vs 36 pg/mL, IQR = 25-80, P = 0.35, respectively). However, on selected study days, patients in the APAP group had significantly lower concentrations of F 2 -isoprostanes (24 pg/mL, IQR = 19-36, vs 36 pg/mL, IQR = 23-55, P = 0.022, respectively, on study day 2) and serum creatinine (1 mg/dL, IQR = 0.6-1.4, vs 1.3 mg/dL, IQR = 0.83-2.0, P = 0.039, respectively, on study day 3). Currently, cell-free hemoglobin and F 2 -isoprostane biomarkers are not used routinely in the care of patients with sepsis or septic shock. Although APAP is used in critically ill patients as an antipyretic or as an analgesic, there is insufficient evidence to justify its use in more selected populations based on biomarkers such as cell-free hemoglobin. Neither the large retrospective study nor the smaller randomized trial by Janz et al 3, 6 evaluated the potential renal protective effects of APAP using validated criteria for diagnosing AKI.
The only randomized, placebo-controlled study powered to evaluate APAP on outcomes such as mortality was conducted by Young et al 7 in critically ill patients with fever and suspected infections. Approximately 83% of the patients in the study had severe sepsis. There was no significant difference between APAP (1 g IV every 6 hours until fever resolution, discontinuation of antimicrobials, ICU discharge or death) or placebo for the primary end point of number of ICU-free days (23 days, IQR = 13-25, vs 22 days, IQR = 12-25, P = 0.07, respectively) or for any of the defined secondary end points or subgroup comparisons.
There are also potential adverse effects of APAP on the development of AKI that must be considered. APAP may cause AKI by proximal tubular cell damage, 12 which may be amenable to early detection with the use of urinary biomarkers. 13 One retrospective cohort study found a 2-fold risk of AKI development in patients with APAP intoxication, regardless of whether hepatic toxicity was observed. 14 In addition, there are case reports of AKI occurring in adults and children receiving therapeutic doses of APAP. 15, 16 This study has some limitations primary related to its retrospective design. There were imbalances between the APAP and no APAP groups with regard to important variables such as severity of illness, comorbidity, and potentially concurrent nephrotoxic medications. Patients in the no APAP group appeared to have a higher severity of illness and comorbidity, which could place them at higher risk for AKI. However, patients in the APAP group were more likely to be coprescribed a nephrotoxic agent. This could have blunted the potential beneficial effects of APAP. We cannot be certain if the net effect of these imbalances influenced our results. Nonetheless, we took several steps to account for this such as conducting a multivariate analysis and also a propensity analysis, which increases the reliability of our results. The propensity score analysis included all these variables and did not show a benefit with APAP use. The dose of APAP used in our study was much lower than that in previous trials, and it is possible that higher doses may have had a greater effect. However, an optimal dose of APAP for prevention of AKI has not been established. We suggest that future studies should assess higher doses such as 1000 mg orally every 6 hours. Our original intent was to incorporate urine output, which is part of the assessment for AKI, if available. It was not possible to accurately retrieve this for all patients. Therefore, we decided that a more accurate and consistent approach for all patients would be to base AKI classification on serum creatinine. Staging was based on rules related to serum creatinine changes from baseline; thus, we were able to use algorithms to automatically categorize stage of AKI. This increased the reliability of the outcome assessment by minimizing any variation and bias that could occur with investigator evaluations. Future studies should incorporate urine output assessment, which may require prospective data collection. 
